Actively Recruiting
Study of CPX-351 Combined With Ivosidenib for Adults With IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Led by M.D. Anderson Cancer Center · Updated on 2026-08-25
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well the combination of CPX-351 and ivosidenib works in treating adults with acute myeloid leukemia AML or high-risk myelodysplastic syndrome MDS that have an IDH1 gene mutation. This phase II trial also studies the safety of this drug combination. The trial aims to find out if this treatment can help control these blood cancers by stopping cancer cell growth. In this study, participants receive CPX-351 intravenously on specific days during induction and consolidation phases, combined with daily oral ivosidenib. The induction phase involves CPX-351 given on days 1, 3, and 5, with ivosidenib taken daily for 28 days. If needed, a second induction cycle may be given. Those who respond proceed to consolidation, receiving CPX-351 on days 1 and 3 plus ivosidenib daily for up to two 28-day cycles. Afterwards, participants may enter a maintenance phase, taking daily ivosidenib for up to two years, with possible continuation after discussion with the study doctor. During the trial, participants will have regular assessments including monitoring for treatment response, side effects, and survival outcomes over up to three years. Researchers will use tests like flow cytometry and molecular evaluations to measure disease status and biomarkers. Follow-up visits occur 30 days after treatment ends and monthly for three years to track long-term outcomes and safety.
CONDITIONS
Brief Title
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Research Team
C
Courtney DiNardo, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here